Stryker earns FDA clearance for new bone and soft tissue removal platform
Article excerpt
Sonopet 3 features enhancements to the company’s Sonopet offerings, such as pulse control, which gives providers added ability to regulate hard and soft tissue resection and Stryker’s Reimagined Integrated Surgical Experience (RISE) technology for a connected surgical workflow. Stryker said it developed the advanced platform with input from hundreds of surgeons who informed key performance improvements, workflow efficiency and clinical priorities. “At Stryker, innovation begins with listening to our customers,” Stryker Neurosurgical VP and GM Mitch Foley said in the announcement. “Every major advancement in Sonopet 3 can be attributed to surgeon feedback, and together we’re elevating the standard in neurosurgery. “They told us they wanted more power, improved ergonomics and enhanced integration, helping them perform with confidence in demanding surgical environments,” he continued. Read more about the world’s largest medtech companies in our 2026 Medtech Big 100 issue of Medical Design & Outsourcing Stryker expects the first clinical cases using the platform to begin this month, with a full commercial launch planned for later this fall. As the orthopedics company expands platforms like Sonopet, it recently invested $400 million in CMR Surgical and entered the soft-tissue robotics market. In the deal, Stryker gains exclusive rights to sell CMR’s Versius platform in the...
Keep reading with a free account
The rest of this article, and every signal for Stryker, is in your free account.
Extracted from this sentence
Stryker Chief Operating Officer Spencer Stiles will become the company’s next CEO, and Lobo will continue to serve as executive chair.
